CEO received an award of 17K WST derivative securities | OQRO Insider tradesWhy it stands out
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Mar 1, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Mar 3, 2026
CEOGrant / award
Context
- Classification
grant award
Code A — grant or award
- Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0000105770-26-000038
- Filed / recorded
Mar 3, 2026, 4:33 PM UTCAdded to OQROOct 2, 2026, 12:29 PM UTC Data qualityVerified: identifiers matched exactly IssuerWEST PHARMACEUTICAL SERVICES INC Reporting personEric Mark Green RelationshipDirector, Officer Officer titlePresident, CEO and Board Chair SecurityStock Option (Right to Buy) TableDerivative (Table II) Transaction dateMar 1, 2026 Acquired / disposedAcquired (A) Footnotes from the filing
- The stock option vests in four equal annual installments beginning on March 1, 2027.
Around the same time
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.